KHDC4 (KH Domain Containing 4, Pre-mRNA Splicing Factor) is a 64.8 kDa RNA-binding protein involved in spliceosome assembly and alternative splicing regulation. It interacts with the PRP19C complex to modulate splice site selection and preferentially binds A/C-rich RNA sequences . The protein is ubiquitously expressed across tissues and localizes to the nucleus and cytoplasm .
Anti-KHDC4 antibodies target epitopes such as the N-terminal region (amino acids 1–241 or 1–250) and are widely used in Western blot (WB), immunohistochemistry (IHC), and ELISA . Synonyms for KHDC4 include KIAA0907, BLOM7, and SNORA80EHG .
A 2022 genome-wide CRISPR-Cas9 knockout study identified KHDC4 as a gene influencing resistance to anti-CD20 monoclonal antibody therapies (e.g., rituximab). KHDC4 knockout cells showed reduced sensitivity to antibody-dependent cellular cytotoxicity (ADCP) and complement-dependent cytotoxicity (CDC), though editing efficiency was lower compared to other hits like IRF8 .
KHDC4 mRNA levels are dynamically regulated by environmental factors:
Western Blot: Detects KHDC4 at ~65 kDa in human liver and tonsil tissues .
IHC: Localizes KHDC4 in paraffin-embedded human tissues (e.g., tonsil) .
Functional Studies: Used to explore KHDC4’s role in cancer (e.g., lymphoma therapy resistance) and developmental disorders .
KHDC4 colocalizes with spliceosomal complexes and regulates mRNA processing . Its expression is modulated by toxins (e.g., glyphosate), pharmaceuticals (e.g., gentamicin), and environmental stressors . These findings highlight its potential as a biomarker for toxicology studies and therapeutic targeting .
KHDC4 is an RNA-binding protein implicated in pre-mRNA splicing. It interacts with the PRP19C/Prp19 complex (also known as the NTC or Nineteen complex), a component of the spliceosome. KHDC4 plays a role in regulating splice site selection and exhibits a preferential binding affinity for RNA sequences rich in adenine and cytosine, particularly poly-C stretches.